ArticleEClinicalMedicine2026
Two-year follow-up of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases: longitudinal insights on depression, anxiety, memory and adaptation in the INSPIRE cohort.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To date, studies of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases (SARDs) have largely been cross-sectional. Our longitudinal study with patients with SARDs from the international INSPIRE cohort aimed to advance knowledge of changes in patient-reported neuropsychiatric symptoms and adapting over time. Methods: We conducted an observational cohort study analysing longitudinal data from the international INSPIRE ( Findings: The modal within-person change between baseline (BL) and follow-up (FU) for the N = 742 participants was zero for all 3 validated tools. Significant improvements at group level over two years were identified for memory scores (BL:16.14 to FU: 13.96, p = 0.002), and all four ADAPT measures (p < 0.05), whereas mean depression (BL:16.61 to FU:16.21, p = 0.303) and anxiety (BL:5.83 to FU:5.36, p = 0.073) scores were unchanged over time. Significant improvements in memory scores were observed in SLE (p = 0.022) and RA/IA (p = 0.009), and in those diagnosed (at baseline) > 10 years (p = 0.016) and between 6 and 9 years (p = 0.020). Interpretation: This study provides evidence against the expectation of progressive memory impairment in most cases in SARDs, including SLE. Lack of improvement in mean depression and anxiety scores over time suggests that many patients with SARDs may benefit from more proactive/assertive rheumatologic disease control, psychiatric intervention, and/or psychosocial support. Early and effective SARDs disease control is required, with timely psychiatric intervention and psychosocial support provided, particularly for the newly diagnosed. Funding: This study was funded by The Lupus Trust.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.